AdvanSix (ASIX) PT Raised to $40 at Stifel on Record Acetone Price Levels
- Wall Street falls with Amazon; S&P 500 posts sixth straight month of gains
- Amazon (AMZN) Plunges After Missing Sales and Guidance Expectations, Analysts Slash PTs to Reflect Weaker Guidance
- Pinterest (PINS) Tops Profit and Sales Views, But Shares Plunges Over 20% on a Big Monthly User Miss to Prompt Two Downgrades
- 'I'm CEO.' New Book Outlines Merger Conversations Between Elon Musk and Tim Cook
- Bullard: Fed should taper this fall, go "fairly rapidly" to end early 2022
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
Stifel analyst Vincent Anderson raised the price target on AdvanSix (NYSE: ASIX) to $40.00 (from $35.00) after updating estimates post-1Q21 to account for the rapid shifts in key product markets, while also adjusting for significant progress in commercializing specialty derivatives.
The analyst stated "Acetone has helped lead the recovery, setting record price levels in 1Q21. While not be counted on for the balance of the year, the spike speaks to the fundamentally improved supply/demand balance in the US following trade case wins in late 2019. As acetone likely recedes, nylon/capro demand should continue to see improved demand, supporting incremental spread expansion (though we remain conservative here in our numbers until proven out). Perhaps most importantly, incremental data from AdvanSix implied upwards of $25 mn of 2021 EBITDA contribution from specialty products that were, until only recently, a benign footnote to revenue commentary. The cyclical recovery on top of improving cash generation keeps us positive on shares. We maintain our Buy rating and raise our target to $40."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SkyWest (SKYW) PT Raised to $60 at Stifel
- Telefonica S.A. (TEF:SM) (TEF) PT Lowered to EUR3.70 at Citi
- UPDATE: Protagonist Therapeutics (PTGX) PT Raised to $93 at Piper Sandler on PN-943 Increasing Likelihood of Success
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!